- Home
- CHPT vs PROK Comparison
CHPT vs PROK Comparison
Compare CHPT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | PROK |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.2M | 359.4M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHPT | PROK |
|---|---|---|
| Price | $11.46 | $1.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $7.50 | ★ $7.88 |
| AVG Volume (30 Days) | 879.4K | ★ 1.3M |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | $893,000.00 |
| Revenue This Year | $7.92 | N/A |
| Revenue Next Year | $13.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $4.44 | $0.87 |
| 52 Week High | $12.97 | $2.65 |
Technical Indicators
Market Signals| Indicator | CHPT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 33.21 |
| Support Level | $5.55 | $0.87 |
| Resistance Level | N/A | $2.01 |
| Average True Range (ATR) | 0.87 | 0.15 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 67.74 | 23.43 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.